Powder: -20°C for 3 years | In solvent: -80°C for 1 year
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 282.00 | |
2 mg | In stock | $ 395.00 | |
5 mg | In stock | $ 597.00 | |
10 mg | In stock | $ 852.00 | |
25 mg | In stock | $ 1,290.00 | |
50 mg | In stock | $ 1,730.00 | |
100 mg | In stock | $ 2,350.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 883.00 |
Description | M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia. |
Targets&IC50 | Menin-MLL:1.4 nM (kd) |
Molecular Weight | 657.87 |
Formula | C37H47N5O4S |
CAS No. | 2363165-42-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7 mg/mL (10.64 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
M‑89 2363165-42-6 Chromatin/Epigenetic Histone Methyltransferase Epigenetic Reader Domain M?89 Inhibitor inhibit inhibitor